Abstract
Schwann cells, the myelin forming cells in the peripheral nervous system, play a key role in the pathology of various inflammatory, metabolic and hereditary polyneuropathies. Advances in identifying growth factors and signaling molecules that are expressed by Schwann cells have paved the way for development of new treatment strategies that are aimed to improve the protective and regenerative properties of Schwann cells in peripheral nerve disorders. These include the exogenous application of growth factors and neurohormones which have been advanced into clinical trials in humans, and transplantation paradigms that have been moved into late stage preclinical models. In this review we will discuss the latest developments in these therapeutic approaches with special regard to peripheral nerve disorders, in which progress in basic research has already been translated into clinical trials, including HIV-associated distal sensory polyneuropathy and diabetic neuropathy.
Keywords: Schwann cells, myelination, regeneration, nerve injury, peripheral nerve, polyneuropathy, diabetic neuropathy, HIV-SN, HIV-Associated Distal Sensory Polyneuropathy, antiretroviral toxic neuropathy, NRTIs, Charcot-Marie-Tooth Disease, CMT1A, HNPP, pmp22, microangiopathy, polyol pathway, Neurotrophins, Gracely Pain Scale, temporal hyperalgesia, Eyrthropoetin, rhEPO, Progesterone, Ascorbic Acid
CNS & Neurological Disorders - Drug Targets
Title: Schwann Cells as a Therapeutic Target for Peripheral Neuropathies
Volume: 9 Issue: 6
Author(s): Helmar C. Lehmann and Ahmet Hoke
Affiliation:
Keywords: Schwann cells, myelination, regeneration, nerve injury, peripheral nerve, polyneuropathy, diabetic neuropathy, HIV-SN, HIV-Associated Distal Sensory Polyneuropathy, antiretroviral toxic neuropathy, NRTIs, Charcot-Marie-Tooth Disease, CMT1A, HNPP, pmp22, microangiopathy, polyol pathway, Neurotrophins, Gracely Pain Scale, temporal hyperalgesia, Eyrthropoetin, rhEPO, Progesterone, Ascorbic Acid
Abstract: Schwann cells, the myelin forming cells in the peripheral nervous system, play a key role in the pathology of various inflammatory, metabolic and hereditary polyneuropathies. Advances in identifying growth factors and signaling molecules that are expressed by Schwann cells have paved the way for development of new treatment strategies that are aimed to improve the protective and regenerative properties of Schwann cells in peripheral nerve disorders. These include the exogenous application of growth factors and neurohormones which have been advanced into clinical trials in humans, and transplantation paradigms that have been moved into late stage preclinical models. In this review we will discuss the latest developments in these therapeutic approaches with special regard to peripheral nerve disorders, in which progress in basic research has already been translated into clinical trials, including HIV-associated distal sensory polyneuropathy and diabetic neuropathy.
Export Options
About this article
Cite this article as:
C. Lehmann Helmar and Hoke Ahmet, Schwann Cells as a Therapeutic Target for Peripheral Neuropathies, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237412
DOI https://dx.doi.org/10.2174/187152710793237412 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herbal Medications for the Management of Diabetes Mellitus: A Review
Current Traditional Medicine Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Entry Inhibitors - A New Class of Aids Drugs
Letters in Drug Design & Discovery Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry Glucose Transport Regulators
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pulmonary Pathology Among Patients with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis
Current Diabetes Reviews Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?
Current Molecular Pharmacology The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Validated Microemulsion Liquid Chromatography-Fluorescence Method for the Quantification of Duloxetine and its Two Main Metabolites in Plasma: Application to Clinical Pharmacokinetic Studies
Current Pharmaceutical Analysis Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Editorial (Thematic Issue: “An Overview on Proteins of Biomedical Importance in Targeted Therapy of Cancer, Duchenne Muscular Dystrophy and Protein Misfolding Associated Neuropathy: Structure Function Relationship, Mechanism of Action, Role of Small Molecule Antagonist and Future Perspective”)
Current Chemical Biology Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews